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OBSERVATIONS
Diabetic Ketosis
Caused by the Insulin
Analog Aspart–
Induced Anti-Insulin
Antibody: Successful
Treatment With the
Newest Insulin
Analog Glulisine
A
nti-insulin antibodies induce im-
munological insulin resistance and
poor diabetic control in insulin-
treated diabetic patients. Recently, the
prevalence and levels of anti-insulin anti-
bodies have remarkably decreased as a
consequence of the purity of insulin
preparations and human insulin (1). The
insulinanaloginsulinaspartexistsashex-
amers that rapidly dissociate into mono-
mersanddimmersafterthesubcutaneous
injection; therefore, insulin aspart is sup-
posed to be less immunogenic than hu-
man recombinant insulin (2).
Herewereportatype1diabeticpatient
who developed diabetic ketosis induced
by severe insulin resistance caused by anti-
insulin antibody after 6 years of insulin
aspart use. He was treated with the newest
insulin analog, insulin glulisine, which re-
sulted in ameliorated glycemic control,
reduced requirement of daily insulin, and
decreased insulin binding rate by anti-
insulin antibody.
A 48-year-old man developed type 1
diabetes in 2000. For the last 6 years, he
has been treated with four daily insulin
injections: three injections of insulin
aspart before breakfast (6–8 units), lunch
(6–8 units), and dinner (6–8 units) and
one of insulin glargine (6 units) at bed-
time. Home monitoring of blood glucose
has not been performed for the last 3
years. He was admitted to hospital be-
cause of hypoglycemia in November
2009 and in July 2010. In August 2010,
he was admitted to our hospital because
of nausea and disturbed consciousness.
His body weight was 49.4 kg and height
179.3 cm (BMI 15.4 kg/m
2). Plasma glu-
cose(868mg/dL)andHbA1c(13.1%)lev-
els were signiﬁcantly elevated. A blood
test revealed elevated serum total ketone
bodies (5,770 mmol/L; normal, ,130
mmol/L) and normal pH (pH 5 7.366),
suggesting the development of diabetic
ketosis. Anti-insulin antibody (
125I-insulin
bindingrate,43.9%;normal,,0.4%)level
was signiﬁcantly elevated. Switching from
insulin aspart to insulin glulisine amelio-
rated his blood glucose levels. His blood
glucose levels were 130–160 mg/dL by us-
ing 4, 4, and 6 units of insulin glulisine
beforebreakfast,lunch,anddinner,respec-
tively, and 6 units of insulin glargine at
bedtime,andhewasdischargedinSeptem-
ber 2010. His HbA1c level and
125I-insulin
binding rate by anti-insulin antibody sig-
niﬁcantly decreased to 11.3 and 35.3%,
respectively, after 4 months of insulin
glulisine use.
The insulin glulisine molecule is more
stable and less likely to self-associate,
compared with human insulin, by the
modiﬁcation of the amino acid sequence
at positions 3 and 29 in the B chain of
human insulin (3). Therefore, unlike other
insulin analogs, insulin glulisine allows
for a viable drug product in the absence
of hexamer-promoting zinc, which may
provide immediate availability of insulin
glulisine at the injection site for absorption
(3). The characteristics of insulin glulisine
such as the rapid absorption and being
zinc-free may be associated with amelio-
ration in anti-insulin antibody–mediated
immunogenic insulin resistance in our
case.
In summary, we suggest that insulin
glulisinemaybesuitableforthetreatment
of patients with other insulin analog–
mediated immunogenic insulin resistance.
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